Synlogic Inc (SYBX)

Synlogic discontinued its Phase 3 study for labafenogene marselecobac (SYNB1934) for PKU, leading to corporate restructuring and a workforce reduction. In September 2023, Synlogic implemented a 1-for-15 reverse stock split to regain Nasdaq compliance. Q3 2024 financial results showed no revenue compared to the previous year, but a reduced net loss due to clinical trial closeouts. As of February 6, 2026, the stock price was $0.59, with a market capitalization of $6.96 million, reflecting a significant decline over the past year.

Synlogic, Inc. does not exhibit traditional demand seasonality due to its focus on developing treatments for rare metabolic disorders and its revenue primarily stemming from collaboration agreements and grants rather than commercial product sales. The company's current operational focus is on strategic alternatives rather than commercialization.

Synlogic, Inc. is a biopharmaceutical company focused on developing Synthetic Biotic medicines for serious diseases, particularly rare metabolic disorders. Their approach involves engineering GI-restricted, oral medicines from probiotics to target specific biological pathways. While they discontinued their Phase 3 study for labafenogene marselecobac (SYNB1934) for PKU, current pipeline candidates include SYNB1353 for classical homocystinuria (HCU), SYNB8802 for enteric hyperoxaluria, and SYNB2081 for gout. They also have early-stage research for cystinuria and IBD, including a collaboration with F. Hoffmann-La Roche Ltd.

Synlogic, Inc. is headquartered in Cambridge, Massachusetts, United States. The company's products are primarily marketed to healthcare providers, biopharmaceutical partners, and research institutions across North America and Europe. Synlogic had aimed to expand its market presence in Europe and North America by 2023.

Synlogic, Inc.'s brand reputation has been negatively impacted by the discontinuation of its Phase 3 program for PKU, leading to corporate restructuring and a shift away from active drug development. The company is now focused on maximizing shareholder value through a strategic transaction, positioning it as a "public cash shell" or a "distressed asset sale" rather than a going concern.

Synlogic, Inc.'s ownership is primarily institutional, with approximately 63.2% to 64.65% of shares held by institutional investors such as Cable Car Capital LLC, NEA Management Company, LLC, and Vanguard Group Inc. Individual insiders hold about 11.08% to 11.9% of the shares, while the public float accounts for approximately 24.27% to 19.8%.